Full Press Release Details
SOUTH SAN FRANCISCO, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, plans to report first quarter 2020 financial results on Thursday, May 7, 2020, after the close of U.S. markets. Following the announcement, the company will host a conference call beginning at 5:00 p.m. ET to discuss its results.
Participants may access the live audio webcast of the teleconference from the “Investors & News” section of CytomX’s website at http://ir.cytomx.com/. Please access the website 15 minutes prior to the start of the call to download and install any necessary audio software.
Audio Conference Call:
| U.S. Dial-in Number: | (877) 809-6037 |
| International Dial-in Number: | (615) 247-0221 |
| Conference ID: | 6282129 |
An archived webcast replay will be available on the Company's website from May 7, 2020, until May 14, 2020.
About CytomX Therapeutics
CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. We are developing a novel class of investigational antibody therapeutics, based on our Probody® technology platform, for the treatment of cancer.
Probody is a U.S. registered trademark of CytomX Therapeutics, Inc.
Investor and Media Contact:
VP, Investor Relations and Corporate Communications